KFF Health Tracking Poll – May 2021: Prescription Drug Prices Top Public’s Health Care Priorities June 3, 2021 Poll Finding The latest KFF Health Tracking Poll explores the public’s views on the U.S. role in distributing COVID vaccines to other countries, health care priorities for Congress, prescription drug regulations and price negotiations, and affordability changes in the COVID-19 relief bill.
How Might Current Federal Drug Pricing Proposals Impact Medicaid? May 24, 2021 Blog Although attention in current federal actions is largely focused on Medicare and private insurance drug prices, federal legislation also has been recently introduced or enacted that would affect Medicaid prescription drug policy.
A New Analysis Takes a Closer Look at Online Contraception Platforms Amid the Pandemic May 18, 2021 News Release Even prior to the COVID-19 pandemic, hormonal contraception became more accessible to many outside of traditional clinical settings through websites or apps that offer contraception via telehealth. To better understand this emerging method of contraceptive access, a new KFF analysis provides a deeper look at telecontraception platforms, offering insights into…
Potential Implications of Policy Changes in Medicaid Drug Purchasing May 4, 2021 Issue Brief This brief examines how leading federal and state policy options related to changes in Medicaid Drug Rebate Program (MDRP), drug pricing, and payment and management of the Medicaid prescription drug would affect state and federal governments as well as private industry (including drug manufacturers, managed care organizations, and pharmacies).
Moving the Needle on Prescription Drug Costs: Using the Innovation Center and Other Demonstration Authority March 25, 2021 Issue Brief This brief examines how the CMS Innovation Center (also known as CMMI) and Section 402 demonstration authority could become pathways for the Biden Administration to implement policy changes related to prescription drug costs.
A Status Report on Prescription Drug Policies and Proposals at the Start of the Biden Administration February 11, 2021 Issue Brief This brief provides a status update on prescription drug final rules advanced by the Trump Administration in its final months related to Medicare, importation, and 340B pricing for insulin and epinephrine, and an overview of key drug pricing proposals related to Medicare and prescription drug prices generally that were voted on but not enacted in the previous Congress that may return to the forefront of health policy discussions in the coming years.
How Can Trump Administration Regulations Be Reversed? January 29, 2021 Issue Brief With the inauguration of President Biden and Democrats holding a slim majority in Congress, policymakers are likely to consider whether and how to reverse various health policy regulations issued by the Trump Administration.
Get Ready for a Lot of Biden Executive Orders on Health Care January 7, 2021 Perspective In this column for the JAMA Health Forum, Larry Levitt explores what President-elect Biden might do to advance his health care vision both through legislation and through executive orders and waivers and demonstrations.
Who Didn’t Get a Second Shingrix Shot? Implications for Multidose COVID-19 Vaccines December 14, 2020 Issue Brief As the U.S. prepares for nationwide distribution of vaccines to combat COVID-19, some are asking whether people who get the first of two doses will return to complete the series. This analysis draws on Medicare Part D prescription drug claims data for the herpes zoster vaccine Shingrix, which also requires two doses, to shed light on this potential challenge of the leading COVID-19 vaccine candidates.
Potential Health Policy Administrative Actions Under President Biden December 8, 2020 Issue Brief This brief outlines the potential health policy actions that President Biden could take using executive authority, based on campaign pledges, and actions that would reverse or modify regulations or guidance issued by the Trump Administration.